Description
Extended front-line bevacizumab treatment associated with favourable outcome in ovarian cancer
Article: Extended front-line bevacizumab treatment associated with favourable outcome in ovarian cancer
€3.03
€3.03
Extended front-line bevacizumab treatment associated with favourable outcome in ovarian cancer
You must be logged in to post a review.
Top
Reviews
There are no reviews yet.